Press Releases

SAVANNAH, GA -- (MARKET WIRE) -- 02/09/12 -- The Savannah Marriott Riverfront Hotel, one of the most reputable hotels on River Street Savannah that is renowned for its service, luxurious accommodations and innovative cuisine, welcomes Chef Stacey Lasure as its new Executive Chef. Chef Lasure has an extensive background in the hospitality industry as well as on the job training. She is most unusual but truly a terrific leader for our Culinary Team.

With over 10 years of industry experience, Chef Lasure has acquired extensive knowledge and skills to competently lead the culinary team and further contribute to the success of the hotel's restaurants on River Street Savannah, GA. Her extensive culinary background with the hotel and natural talent made her the best choice for the position. Chef Lasure has been a part of the Savannah Marriott Riverfront's culinary team since November 2000, where she served as a Banquet Chef until March 2005. From March 2005 to November 2012, she served as Executive Sous Chef for the Savannah Marriott Riverfront Hotel.

In her new role, Chef Lasure will be in charge of the overall operation and administration of the culinary team at this full-service Savannah hotel. Under the direction of the new Chef, this Savannah hotel's restaurants will continue offering its delicious contemporary menu of American fare while refining the services and quality of the food. Chef Lasure believes in the words of David Bly ~ "Striving for success without hard work is like trying to harvest where you haven't planted."

"My entire professional life has been in some form of customer service. The occupations were varied and at times vastly different, but the underlying principle of service was always the same. Without the customer, we have no reason to do what we do," says Chef Lasure. "Cooking has always been an intrinsic part of my life; even when it had nothing to do with my job. Now that it is my job, I find that I get as much enjoyment feeding 500 people in a ballroom as I do from feeding 10 people in my home. There is a great deal of satisfaction in getting up every day and going to a job where I get to do something that I love, but the best part of my day is talking to the guests after they've eaten and hearing 'the food was wonderful.'"

As one of the premier hotels that offer beautiful Savannah wedding locations, the Savannah Marriott Riverfront Hotel sets a new standard among Savannah, GA hotels. Boasting elegant guest rooms and suites with upscale amenities, comfortable bedding, and high-speed Internet, guests will enjoy a wonderful stay at this hotel. Guests staying in the Junior and Executive suites and Concierge level rooms can enjoy the hotel's luxurious accommodations that are unrivaled and beautiful views of the waterscape. This hotel also offers convenient access to renowned attractions, including antique shops, art galleries, shopping, Bonaventure Cemetery, Fort Pulaski Monument, Old Fort Jackson and the Savannah Theatre.

About the Savannah Marriott Riverfront Hotel A favorite among leisure and business travelers, the Savannah Marriott Riverfront Hotel is a full service hotel that offers 36,000 square feet of meeting and event space that is perfect for social and business functions. Located among the Savannah hotels near Civic Center, guests staying at the Savannah Marriott Riverfront will be right on the Historic Riverfront where they can enjoy the wonderful hotel amenities and nearby attractions.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=1882492

Add to Digg Bookmark with del.icio.us Add to Newsvine

CONTACT:
Jody McIntyre
Savannah Marriott Riverfront
1-912-233-7722
Email Contact

Source: Marriott International

New NCCN Guidelines for Patients™: Colon Cancer and Updated NCCN Guidelines for Patients™: Prostate Cancer are now available on-line at NCCN.com. The same authoritative source referenced by physicians and other health care professionals is now written for and available to patients and their caregivers.

FORT WASHINGTON, Pa.--(BUSINESS WIRE)-- In order to provide people with cancer and their caregivers state-of-the-art treatment information in patient-friendly language, the National Comprehensive Cancer Network® (NCCN®) has developed two new publications: a new release of the NCCN Guidelines for Patients™: Colon Cancer and an update to the NCCN Guidelines for Patients™: Prostate Cancer. The guidelines provide a framework to help people with cancer talk with their physician about the best treatment options.

According to the 2012 annual report from the American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) (Seigel, Naishadham, & Jemal, 2012), colon cancer is the fourth most common cancer in the United States. The newly released NCCN Guidelines for Patients™: Colon Cancer include a treatment guide covering the different stages of colon cancer from early detection and diagnosis throughout treatment, across the entire continuum of care. The guidelines describe tests and treatment options for colon cancer, along with treatment side effects. A thorough glossary is included to aid patients with medical terminology. These guidelines suggest the best practice for colon cancer care and support enrollment into clinical trials when appropriate.

Prostate cancer is a complex disease; fortunately there is a dearth of sound data to support treatment recommendations. NCCN’s Guidelines for Patients™: Prostate Cancer cover several variables (including life expectancy, disease characteristics, predicted outcomes, and patient preferences) that should be considered by the patient and the physician in tailoring prostate cancer therapy to the individual patient. The guidelines provide information that will help people with prostate cancer and their friends and family understand the cancer, and further to help them talk with their cancer care team about the best treatment options. In particular, the guidelines give treatment recommendations based on the characteristics of the cancer possible side effects of treatments, and a side-by-side comparison of the main benefits and disadvantages of the treatments for prostate cancer.

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are the most widely used guidelines in oncology practice; physicians around the globe use the NCCN Guidelines when determining appropriate cancer treatment for their patients. The NCCN Guidelines for Patients™ present the same information that physicians use when making treatment decisions for people with cancer, and provide it in an easy-to-understand format.

The NCCN Guidelines for Patients™: Colon Cancer and Prostate Cancer are available free of charge on-line at NCCN.com and NCCN.org. The updated NCCN Guidelines for Patients™: Prostate Cancer is also available in print booklet format. To request a hard copy of this resource, e-mail patientguidelines@nccn.org.

Through the support of the NCCN Foundation, NCCN now offers a library of nine NCCN Guidelines for Patients™, including those on breast, colon, ovarian, non-small cell lung and prostate cancers, as well as chronic myelogenous leukemia, malignant pleural mesothelioma, melanoma, and multiple myeloma. All of these Guidelines are available free of charge at NCCN.com, which also features informative articles for patients and caregivers. These guidelines are also featured on NCCN.org.

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.

The NCCN Member Institutions are: City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/University of Tennessee Cancer Institute, Memphis, TN; Stanford Comprehensive Cancer Center, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; UNMC Eppley Cancer Center at The Nebraska Medical Center, Omaha, NE; The University of Texas MD Anderson Cancer Center, Houston, TX; and Vanderbilt-Ingram Cancer Center, Nashville, TN.

Clinicians, visit NCCN.org. Patients and caregivers, visit NCCN.com.

NCCN aims to provide people with cancer and the general public state-of-the- art cancer treatment information in easy-to-understand language. The NCCN Guidelines for Patients™, translations of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), are meant to help patients with cancer talk with their physician about the best treatment options. These guidelines do not replace the expertise and clinical judgment of the physician.

National Comprehensive Cancer Network (NCCN)Mary Buemi, 215-690-0576buemi@nccn.org

Source: National Comprehensive Cancer Network (NCCN)

LITTLE ROCK, Ark., Feb. 9, 2012 (GLOBE NEWSWIRE) -- Windstream Corp. (Nasdaq: WIN) today announced that it is seeking the consent of its lenders to amend and restate its existing senior secured credit facilities to, among other things: (i) provide for the incurrence of $280 million of additional term loans, the proceeds of which will be used to partially repay the credit facility revolver (without any reduction in commitments); (ii) extend the maturity of certain existing term loans; (iii) provide for the ability to refinance and extend the maturity of any term loan or revolving loan with the consent of the affected lenders; and (iv) modify certain other definitions and provisions.

The company expects to complete the amendment and restatement, subject to the receipt of required consents and other customary conditions, in February 2012.

This press release is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any securities of Windstream.

About Windstream

Windstream Corp. (Nasdaq: WIN) is a leading provider of advanced network communications, including cloud computing and managed services, to businesses nationwide. The company also offers broadband, phone and digital TV services to consumers primarily in rural areas. Windstream has more than $6 billion in annual revenues and is listed on the S&P 500 index. For more information, visit www.windstream.com.

The Windstream Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8314

Windstream claims the protection of the safe-harbor for forward-looking statements contained in the Private Securities Litigation Act of 1995. Forward-looking statements are subject to uncertainties that could cause actual future events and results to differ materially from those expressed in the forward-looking statements. These forward-looking statements are based on estimates, projections, beliefs and assumptions that Windstream believes are reasonable but are not guarantees of future events and results. Actual future events and results of Windstream may differ materially from those expressed in these forward-looking statements as a result of a number of important factors. Factors that could cause actual results to differ materially from those contemplated above include, among others: further adverse changes in economic conditions in the markets served by Windstream; the extent, timing and overall effects of competition in the communications business; continued access line loss; the impact of new, emerging or competing technologies; the adoption of inter-carrier compensation and/or universal service reform proposals by the Federal Communications Commission or Congress that results in a significant loss of revenue to Windstream; the risks associated with the integration of acquired businesses or the ability to realize anticipated synergies, cost savings and growth opportunities; unexpected adverse results related to our data center migration; for our competitive local exchange carrier ("CLEC") operations, adverse effects on the availability, quality of service and price of facilities and services provided by other incumbent local exchange carriers on which our CLEC services depend; the availability and cost of financing in the corporate debt markets; the potential for adverse changes in the ratings given to Windstream's debt securities by nationally accredited ratings organizations; the effects of federal and state legislation, and rules and regulations governing the communications industry; material changes in the communications industry that could adversely affect vendor relationships with equipment and network suppliers and customer relationships with wholesale customers; unfavorable results of litigation; unfavorable rulings by state public service commissions in proceedings regarding universal service funds, inter-carrier compensation or other matters that could reduce revenues or increase expenses; the effects of work stoppages; the impact of equipment failure, natural disasters or terrorist acts; earnings on pension plan investments significantly below our expected long term rate of return for plan assets; and those additional factors under the caption "Risk Factors" in Item 1A of this annual report and those additional factors under the caption "Risk Factors" in Windstream's Form 10-K for the year ended December 31, 2010, and in subsequent Securities and Exchange Commission filings. In addition to these factors, actual future performance, outcomes and results may differ materially because of more general factors including, among others, general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. Windstream undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The foregoing review of factors that could cause Windstream's actual results to differ materially from those contemplated in the forward-looking statements should be considered in connection with information regarding risks and uncertainties that may affect Windstream's future results included in Windstream's filings with the Securities and Exchange Commission at www.sec.gov.

CONTACT: Media Contact:
         David Avery, 501-748-5876
         david.avery@windstream.com

         Investor Contact:
         Mary Michaels, 501-748-7578
         mary.michaels@windstream.com

VANCOUVER, BRITISH COLUMBIA -- (MARKET WIRE) -- 02/09/12 -- Silvercorp Metals Inc. ("Silvercorp" or the "Company") (TSX: SVM)(NYSE: SVM) today announced that its Board of Directors has declared its third quarter fiscal 2012 dividend of CAD$0.025 per share to be paid on or before April 21, 2012 to shareholders of record at the close of business on March 31, 2012. Today's declared quarterly dividend is the second Silvercorp has announced since increasing its dividend by 25% from the previously paid CAD$0.02. The dividends are considered eligible dividends for Canadian tax purposes.

The Company first began paying dividends in 2007 with an annual dividend of $0.05.

About Silvercorp Metals Inc.

Silvercorp Metals Inc. is engaged in the acquisition, exploration, development and mining of high-grade silver-related mineral properties in China and Canada. Silvercorp is the largest primary silver producer in China through the operation of the four silver-lead-zinc mines at the Ying Mining District in the Henan Province of China. Silvercorp recently acquired the XBG and XHP silver-gold-lead-zinc mines nearby the Ying Mining District in Henan Province, further consolidating the region. Silvercorp has commenced production at its second production foothold in China, the BYP gold-lead-zinc project in Hunan Province, and is currently constructing the mill and related facilities in preparation for mining at the GC silver-lead-zinc project in Guangdong Province. In Canada, Silvercorp is preparing an application for a Small Mine Permit for the Silvertip high grade silver-lead-zinc mine project in northern British Columbia to provide a further platform for growth and geographic diversification. The Company's shares are traded on the New York Stock Exchange (symbol: SVM) and Toronto Stock Exchange (symbol: SVM) and are included as a component of the S&P/TSX Composite and the S&P/TSX Global Mining Indexes.

Contacts:
Silvercorp Metals Inc.
Rui Feng
Chairman/CEO
(604) 669-9397, Toll Free Phone: 1-888-224-1881

Silvercorp Metals Inc.
Lorne Waldman
Corporate Secretary
(604) 669-9397, Toll Free Phone: 1-888-224-1881
(604) 669-9387 (FAX)
info@silvercorp.ca
www.silvercorp.ca

Source: Silvercorp Metals Inc.